Triple negative breast cancer (TNBC) represents the clinical subtype of breast cancer that is negative for immunohistochemistry (IHC)-based assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) amplification. This evidence concerns the gene PGR and breast cancer.